A novel mutant-enriched liquidchip technology for the qualitative detection of somatic mutations in <i>KRAS</i> gene from both serum and tissue samples

Wu, Shiyang; Zhu, Zhengyan; He, Jinzhi; Luo, Xiaodi; Xu, Jianbing; Ren-Heidenreich, Lifen

doi:10.1515/cclm.2010.227

Cited by 20 publications

(17 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the prevalence of gene mutations and molecular segmentation in other tumor types (as well as our previously published data; Hou et al), 34 'hot spot' EGFR, K-ras, B-raf, and PIK3CA gene mutations were screened for using the mutant-enriched PCR method. 35 The method was performed by SurExam Bio-Tech Co. Ltd., Guangzhou Technology Innovation Base, Science City, Guangzhou, PRC. Positive results were further confirmed by PCR-direct sequencing.…”

Section: Her2 Fluorescencementioning

confidence: 99%

Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery

Zhang

Jiang

et al. 2014

Laboratory Investigation

View full text Add to dashboard Cite

The purpose of this study was to establish and characterize patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mice for utilization in antitumor drug discovery. A total of 96 esophageal squamous cell carcinoma (ESCC) tissues from Chinese patients were transplanted subcutaneously into immunodeficient mice. Histology, EGFR, K-ras, B-raf, and PIK3CA mutations, and HER2 gene amplifications were analyzed in both patient tumors and mouse xenograft tissues using immunohistochemistry, mutant-enriched liquid chip sequencing and fluorescence in situ hybridization assays, respectively. Furthermore, in vivo efficacy studies using five PDECX mice harboring a variety of genetic aberrations were performed using the chemotherapy agents 5-fluorouracil (5-FU) and cisplatin. Thirty-seven PDECX mouse models were successfully established in immunodeficient mice. Pathological analysis revealed similar histological architecture and degrees of differentiation between patient ESCC and xenografted tumors. No mutations were identified in EGFR, K-ras, and B-raf genes in either xenograft models or patient ESCC tissues. In contrast, PIK3CA gene mutations were detected in 12.5% (12/96) ESCC patients and 18.9% (7/37) PDECX models. Interestingly, patient ESCC tissues exhibiting HER2 overexpression or gene amplification were unable to survive in immunodeficient mice. Further analysis showed that PDECX models carrying HER2 2 þ expression had no response to 5-FU/cisplatin, compared with HER2-negative models. In conclusion, a panel of PDECX mouse models, which include PIK3CA mutant and HER2-positive models, was established and characterized thus mimicking the current clinical genetic setting of esophageal carcinoma. The sensitivity of HER2-negative ESCC models to chemotherapy supports stratification approaches in the treatment of esophageal carcinoma patients and warrants further investigation of the impact of PI3KCA on treatment response.Laboratory Investigation (2014) 94, 917-926;

show abstract

Section: Her2 Fluorescencementioning

confidence: 99%

Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery

Zhang

Jiang

et al. 2014

Laboratory Investigation

View full text Add to dashboard Cite

show abstract

“…Many technologies are available for analyzing circulating nucleic acid [16,17]. MeL technology was developed by Wu [18] to detect KRaS mutations using serum or formalin-fixed and paraffin-embedded samples. The technique is a method of high sensitivity, high reliablity and high throughput [18].…”

Section: Resultsmentioning

confidence: 99%

“…MeL technology was developed by Wu [18] to detect KRaS mutations using serum or formalin-fixed and paraffin-embedded samples. The technique is a method of high sensitivity, high reliablity and high throughput [18]. In the current study, a very low egfR mutation rate was found (1/35, 2.8%), which was consistent with reports in literatures [11][12].…”

Section: Resultsmentioning

confidence: 99%

Identifying EGFR Mutations from SCLC Patient Plasma by Mutant-Enriched Liquidchip Technology

Cheng

et al. 2014

Adv Clin Exp Med

View full text Add to dashboard Cite

Background. epidermal growth factor receptor (egfR) tyrosine kinase inhibitors (TKI) such as erlotinib and gefitinib are targeted drugs for the kinase domain of egfR. They are widely used for the treatment of non-small cell lung cancer (NScLc). The egfR exon 19 deletion mutation and the L858R mutation in exon 21 comprise approximately 90% of the somatic mutations in NScLc patients that respond to egfR TKI. Several recent studies have also reported that small cell lung cancer (ScLc) patients with egfR mutations responded to gefitinib. further study, however, has been limited due to the difficulty obtaining tumor specimens from ScLc patients. Objectives. The aim of this study was to explore the egfR mutation status in ScLc patients by plasma analysis. Material and Methods. Plasma samples from ScLc patients were collected for mutant-enriched liquidchip (MeL) analysis to identify the egfR mutations in exon 19 and 21. Results. The exon 19 deletion mutation was detected in one out of 35 patients (a female non-smoker). No exon 21 mutations were found. Conclusions. a prevalence of egfR mutations in ScLc is rare, and occurs most frequently in females and nonsmokers (Adv Clin Exp Med 2014, 23, 2, 191-195).

show abstract

“…Actually, Denys et al [18] also used LNA-modified oligonucletoide probes for JAK2 V617F detection and improved the sensitivity of the real-time PCR assay to 0.4% mutant allele. In our opinion, further reliable improvement of sensitivity of the bead-based assay below 1% mutant allele would be possible through mutant enrichment by initial two-step PCR amplification with intermediate BsaXI restriction, similar to the approach reported for KRAS mutation detection [19].…”

Section: (Received 11 April 2011; Accepted 24 April 2011)mentioning

confidence: 88%

Rapid quantification ofJAK2V617F allele burden using a bead-based liquid assay with locked nucleic acid-modified oligonucleotide probes

Shivarov

Ivanova²,

Hadjiev³

et al. 2011

Leukemia & Lymphoma

View full text Add to dashboard Cite

A novel mutant-enriched liquidchip technology for the qualitative detection of somatic mutations in KRAS gene from both serum and tissue samples

Abstract: A novel, qualitative, sensitive, reliable and high throughput liquidchip technology has been developed for detecting KRAS mutations using clinical serum and formalin-fixed and paraffin-embedded samples.

Cited by 20 publications

References 14 publications

Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery

Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery

Identifying EGFR Mutations from SCLC Patient Plasma by Mutant-Enriched Liquidchip Technology

Rapid quantification ofJAK2V617F allele burden using a bead-based liquid assay with locked nucleic acid-modified oligonucleotide probes

Contact Info

Product

Resources

About